Melanoma Clinical Trials in New York

Showing 161-180 of 341 trials

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

NCT02978443

Participants with advanced or metastatic mucosal melanoma (cohort A) and acral lentiginous melanoma (cohort B) eligible for treatment with nivolumab in combination with ipilimumab followed by nivolumab therapy will submit tissue blocks from tumors of malignant melanoma for histopathology review and immunohistochemistry analysis at Georgetown University-Lombardi Comprehensive Cancer Center. Pretreatment blood will be drawn and stored in the Melanoma Research Foundation Breakthrough Consortium Virtual Repository at each participating institution. At the end of participation, samples will be sent to Georgetown University-Lombardi Comprehensive Cancer Center for processing and storage. An optional pretreatment biopsy of an accessible tumor lesion will be performed in a subset of enrolled patients. Patients will receive nivolumab in combination with ipilimumab according to the standard FDA approved treatment regimen.

Acral Lentiginous MelanomaMucosal Melanoma

Georgetown University14 participantsStarted Jul 2017

Washington D.C., District of Columbia, United States • Washington D.C., District of Columbia, United States • Tampa, Florida, United States +2 more locations

COMPLETEDPhase 1/2< 1 mile

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

NCT03665285

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

Advanced or Metastatic Solid TumorsLung CancerBreast Cancer+6 more

NextCure, Inc.109 participantsStarted Oct 2018

Los Angeles, California, United States • New Haven, Connecticut, United States • Hackensack, New Jersey, United States +3 more locations

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Melanoma Trials in Other Cities

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Study in Subjects With Small Primary Choroidal Melanoma

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Other Conditions in New York